instruction:
Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.
question:
Paragraph: After nearly disappearing in the United States, the bloodsucking pests have made a comeback in recent years, quickly infesting apartment buildings and stubbornly resisting common insecticides. The city of New York alone spends as much as $40 million a year in bedbug control. A study of bedbug genetics presented on Tuesday at the American Society of Tropical Medicine and Hygiene meeting in Philadelphia now suggests why. A team of entomologists led by Coby Schal and Ed Vargo of North Carolina State University studied the genes of bedbugs infesting three multistory apartment buildings in North Carolina and New Jersey and found very low genetic diversity — meaning most of them were very close relatives. They were so close in fact that the team suspects it may have taken just one or two founder insects to start an entire infestation. “We find that bedbug infestations basically start from a very small number of individuals,” Schal said in a telephone interview. “A single mated female bedbug starts the infestation. She gives rise to offspring and those offspring mate with each other and with their mother,” he said. “This is different from many animals,” he said, mostly because close inbreeding can result in genetic deformities, adding, “In humans, it is taboo.”   But he said there are some animals that can withstand such close inbreeding without experiencing detrimental effects including cockroaches. Schal said this may be a trait of insects that have evolved an association with humans and rely on them to get from place to place. Typically this happens when humans bring infested furniture into their homes, and he warns people to inspect second-hand furniture carefully. “There is a myth out there that bedbugs get transported on people,” Schal said. Unlike ticks, the wingless, reddish-brown insects stay attached to people for a blood meal for just 5 to 10 minutes, he said. “The chances that a person is carrying bedbugs on them is quite low.”   According to the U.S. Centers for Disease Control and Prevention, bedbugs do not carry disease, but their bites can cause severe itching and a whole lot of anxiety. Schal said his findings are not likely to lead to new insecticides for bedbugs, but they do underscore the need to move fast once bedbugs are detected. “If you don’t deal with them early they can spread thorough   a building very quickly,” he said. Claim: All in the family: Inbreeding key to bedbug spread.
answer:
Inbreeding may be the secret to the bedbug’s success, U.S. researchers said on Tuesday.


question:
Paragraph: The trial results on patients with a gene anomaly known as NTRK fusion, which occurs in less than 1 percent across a range of tumor types, were presented at the annual congress of the European Society for Medical Oncology (ESMO) in Munich on Sunday. Germany’s Bayer and U.S. partner Loxo, in turn, released data for their rival compound larotrectinib, which slightly improved on previous high-efficacy readings in an enlarged trial. Traditionally, oncologists have made treatment decisions based on where in the body a tumor started, increasingly helped by the growing knowledge of cancer’s complex genetic drivers. Under the tumor-agnostic approach, also known as pan-tumor, drugmakers skip the organ-of-origin perspective and regroup patients based only on signature genetic mutations, but success in real life will depend on the fast spread of comprehensive gene-sequencing tools for tissue samples. Individually, the mutations are so rare that cancer units are seen as unlikely to run dedicated tests for each. Roche’s Foundation Medicine supplies the comprehensive kits, competing with Thermo Fisher Scientific and Caris Life Sciences. “It’s one of the reasons we acquired Foundation Medicine, to make this comprehensive genomic profiling routine and upfront in the course of the disease,” said Daniel O’Day, the head of Roche’s Pharmaceuticals division. Loxo’s larotrectinib pill, co-developed with Bayer, was last year shown to shrink tumors in 75 percent of patients with the NTRK fusion gene anomaly, occurring in the lung, pancreas, or more than a dozen other organs. On Sunday, the response rate to larotrectinib within an enlarged group of 122 trial participants - up from 55 initially and now spanning 24 tumor types - was shown to be 81 percent. Roche said the readings from the two NTRK fusion trials were not comparable because they are made up of different patient types. Loxo’s study, for instance, included some cancers in children, while Roche plans to investigate those separately. The Roche compound is designed to tackle several oncogenic mutations and last month, it unveiled data here on entrectinib pushing back tumors in 77 percent of lung cancer patients with a mutation called ROS1. Merck & Co’s Keytruda in May last year became the first drug to win approval for pan-tumor use, though that remains a relatively small market for the mega-selling drug. Bayer and Loxo are testing a second pan-tumor drug, LOXO-195. Roche Pharmaceutical’s O’Day welcomed a wider field. “Both things have to happen: You need genomic profiling and you need enough targeted medicines to encourage physicians to make that diagnosis upfront very complete. This is the world we’re entering,” he said. Though response rates could encourage a race for more such drugs, the need for suitable gene mutations or fusions will be a tall order, said oncologist Ulrik Lassen of Copenhagen’s Rigshospitalet, who co-authored the larotrectinib study. “You need to screen a lot of patients to find the needle in the haystack and the method is complicated, costly and time-consuming. When we get better at using these technologies, we can find more oncogenic fusions and companies will be smart enough to find the agents that target them.”  Roche acquired entrectinib as part of its takeover deal with U.S. cancer drug specialist Ignyta Inc for $1.7 billion, agreed in December last year. Immuno-oncology remains another major business area for Roche, which also released positive results on using its Tecentriq drug in a group of breast cancer patients with a particularly poor prognosis. Claim: Roche takes on Loxo, Bayer in gene-defined cancer class.
answer:
Roche’s entrectinib cancer pill was shown to shrink tumors in 57 percent of patients within a group that can only be identified via genetic profiling, as the Swiss drugmaker challenges an alliance of Bayer and Loxo Oncology in a new targeted treatment area.


question:
Paragraph: The private university in Durham submitted claims for dozens of research grants that contained falsified or fabricated information that unjustly drained taxpayer money from the National Institutes of Health, the Environmental Protection Agency and other federal agencies, the U.S. Justice Department said. The school said it is repaying grant money and related penalties. “Taxpayers expect and deserve that federal grant dollars will be used efficiently and honestly,” local U.S. Attorney Matthew G.T. Martin said in a statement. “May this serve as a lesson that the use of false or fabricated data in grant applications or reports is completely unacceptable.” The lawsuit was first filed in 2015 by whistleblower and former Duke employee Joseph Thomas. The Justice Department took it over afterward. The suit claims the faked research was conducted by former research technician Erin Potts-Kant, who was supervised by pulmonary medicine researcher William Michael Foster. Foster’s lab experimented with mice, seeking to determine the effects of inhaling diesel exhaust, among other tests. Several research papers by Foster’s team were later retracted. “We expect Duke researchers to adhere always to the highest standards of integrity, and virtually all of them do that with great dedication,” university President Vincent Price said in a statement. “When individuals fail to uphold those standards, and those who are aware of possible wrongdoing fail to report it, as happened in this case, we must accept responsibility, acknowledge that our processes for identifying and preventing misconduct did not work, and take steps to improve.” The settlement was announced on the same day that U.S. District Judge Catherine Eagles had scheduled a hearing on why the deal supposedly struck in November hadn’t been finalized by the Justice Department. The government alleged that between 2006 and 2018 Duke knowingly submitted faked data to federal agencies in 30 grants. The university had warning signs that some of the research was fraudulent but didn’t act until discovering in 2013 that Potts-Kant had siphoned off money for spending on clothes and other items, the lawsuit said. Duke University said the technician pleaded guilty to two counts of forgery in state court and paid the school restitution. Foster retired in 2015, university spokesman Michael Schoenfeld said. Thomas, the whistleblower, will get $33.75 million from the settlement, the government said. Duke is still dealing with a different research scandal dating back more than a decade. Duke medical professor Dr. Anil Potti engaged in misconduct while researching treatments in human cancer patients, U.S. Health and Human Services Department investigators said in 2015. Potti’s studies were published in top medical journals including the New England Journal of Medicine and Lancet Oncology between 2006 and 2009. In a settlement reached with the federal health agency, Potti did not acknowledge liability but agreed to have all his research supervised until 2020. Potti left Duke in 2010. Duke settled lawsuits brought by patients and estates of patients who participated in those medical trials. As a result of both cases, the National Institutes of Health last year required Duke University researchers to increase their reporting of how federal grant money was being spent. ____ Follow Emery P. Dalesio on Twitter at http://twitter.com/emerydalesio . His work can be found at https://apnews.com/search/emery%20dalesio. Claim: Duke University pays $112M to settle faked-research lawsuit.
answer:

Duke University will pay $112 million to settle a whistleblower lawsuit after federal prosecutors said a research technician’s fake data landed millions of dollars in federal grants, the school and the government said Monday.